{"url_path":"/sec/mbrx/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS **","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-017034-index.html","accession_number":"0001437749-26-017034","cik":"0001659617","ticker":"MBRX","issuer_name":"Moleculin Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-017034-index.html","primary_entity_key":"0001659617","primary_entity_name":"Moleculin Biotech, Inc."},"word_count":43,"has_tables":true,"body_markdown":"**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS **\n\n \n\nOther than as previously disclosed in our Current Report on Form 8-K on February 20, 2026, we did not sell any unregistered equity securities during the fiscal quarter ended March 31, 2026."}